Epigenomics AG Enters into R&D Collaboration with Myriad Genetics Inc. to Discover DNA Methylation Biomarkers
Under the agreement, Epigenomics will use its proprietary Differential Methylation Hybridization (DMH) microarray platform to perform genome-wide DNA methylation profiling on samples provided by Myriad and compare these profiles to identify DNA methylation biomarkers associated with sensitivity and resistance to the drug.
Epigenomics will also apply its OncoSign(TM) approach that is offered in collaboration with its partner CellTrend GmbH for fast track identification of DNA methylation biomarkers for the drug in an established panel of human tumor cell lines. Financial details were not disclosed.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.